Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist
نویسندگان
چکیده
منابع مشابه
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
© Touch MEdical MEdia 2013 Abstract optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. however, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). almost half of patients treated with basal insulin and oral anti-diabetic drugs (oads) do not achieve their glycated haemoglobin (hba1c) goal...
متن کاملGlucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related condi...
متن کاملEFFECTS OF AEROBIC TRAINING ON DIPEPTIDYL PEPTIDASE-4 AND GLUCAGON-LIKE PEPTIDE-1 IN OBESE WOMEN WITH TYPE 2 DIABETES
Background: Obesity increases the risk of developing type 2 diabetes with regard to the hormones involved. The purpose of this quasi-experimental study was to investigate the effect of aerobic exercise on Dpp-4 and GLP-1 in obese women with type 2 diabetes. Methods: From among obese women with type-2 diabetes mellitus 35-50 years old referred to the Diabetes Association of Saveh, 20 people wer...
متن کاملSerum Glucagon-Like Peptide-1 Changes in Women with Type 2 Diabetes Following a Four Weeks Aerobic Exercise
Objective: The objective of this study was to investigate the effect of four weeks aerobic training on serum glucagon-like peptide-1 (GLP-1) in women with type 2 diabetes mellitus (T2DM). Materials and Methods: Twenty T2DM patients (33-53 years) were randomly assigned into control (n=10) and experimental (n=10) groups. The main intervention included running on treadmill, reaching 55 to 80% o...
متن کاملAn overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2020
ISSN: 0025-7974,1536-5964
DOI: 10.1097/md.0000000000021939